azimexon has been researched along with Experimental Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruley-Rosset, M; Florentin, I; Goutner, A; Mathé, G; Serrou, B | 1 |
| Bicker, U; Maus, W; Probst, E | 1 |
| Chirigos, MA; Lauer, L; Papademetriou, V; Stylos, WA | 1 |
3 other study(ies) available for azimexon and Experimental Neoplasms
| Article | Year |
|---|---|
Three new agents for immunotherapy trials: azimexon, bestatin, and tuftsin.
Topics: Adjuvants, Immunologic; Animals; Aziridines; Azirines; Cytotoxicity, Immunologic; Drug Evaluation, Preclinical; Immunoglobulin Fragments; Immunotherapy; Leucine; Mice; Neoplasms, Experimental; T-Lymphocytes; Tuftsin | 1982 |
Influence of the immunostimulating compound azimexone (2-[2-Cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane) on the number of metastases in the Lewis lung carcinoma in mice.
Topics: Animals; Aziridines; Azirines; Lung Neoplasms; Male; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Transplantation, Isogeneic | 1981 |
The immunomodulatory effect on BM 12.531 (azimexon) on normal or tumored mice: in vitro and in vivo studies.
Topics: Animals; Ascitic Fluid; Aziridines; Azirines; Cells, Cultured; Hypersensitivity, Delayed; Immunity, Cellular; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; X-Rays | 1980 |